TBPH
$14.33+0.32 (+2.28%)
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
Recent News
Theravance's Q4 Earnings and Revenues Miss Estimates
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.
All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy
Theravance Bio (TBPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -86.47% and -23.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Theravance Bio: Q4 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. AP) — Theravance Biopharma Inc. TBPH) on Thursday reported fourth-quarter profit of $61 million.
Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates
Assertio (ASRT) delivered earnings and revenue surprises of +39.02% and +185.10%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?